QGEN Stock Falls -14% In 7-Day Losing Spree On Increased Short Interest
Qiagen (QGEN) – a provider of molecular biology consumables and diagnostic assays – hit a 7-day losing streak, with cumulative losses over this period amounting to -14%. The company’s market cap has crashed by about $1.5 Bil over the last 7 days and currently stands at $9.3 Bil.
The stock has YTD (year-to-date) return of 4.5% compared to -0.9% for S&P 500. This calls for a re-evaluation of the stock’s valuation to find out whether this is an opportunity or a trap.
What Triggered The Slide?
[1] Significant Increase in Short Interest
- Amazon.com Stock On A Winning Streak: Time To Get In Or Book Profits?
- Is H&R Block Stock Optimizing Returns Through the Denominator Effect?
- PLTR Stock: What Does Its Valuation Imply?
- Where Will Apple Stock Be In 3 Years?
- NVDA Stock: The Setup Hiding In Plain Sight
- What QCOM Options Know That The Stock Price Won’t Tell You
- 20% increase in short interest reported in February
- Stock down 9.4% since last earnings report
- Impact: Sustained Institutional Selling, Negative Price Momentum
Opportunity or Trap?
Below is our take on valuation.
There are only a couple of things to fear in QGEN stock given its overall Strong operating performance and financial condition. Considering stock’s Moderate valuation, we think it is Attractive (For details, see Buy or Sell QGEN).
But here is the real interesting point.
You are reading about this -14% move after it happened. The market has already priced in the news. To avoid the next loser before the headlines, you need predictive signals, not notifications. Our High Quality Portfolio has a risk model designed to reduce exposure to losers.
Returns vs S&P 500
The following table summarizes the return for QGEN stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | QGEN | S&P 500 |
|---|---|---|
| 1D | -0.8% | -0.2% |
| 7D (Current Streak) | -13.7% | -1.4% |
| 1M (21D) | -15.6% | -2.2% |
| 3M (63D) | -8.7% | -1.3% |
| YTD 2026 | -4.5% | -0.9% |
| 2025 | 1.5% | 16.4% |
| 2024 | 5.5% | 23.3% |
| 2023 | -12.9% | 24.2% |
Gains and Losses Streaks: S&P 500 Constituents
There are currently 10 S&P constituents with 3 days or more of consecutive gains and 101 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 6 | 37 |
| 4D | 0 | 31 |
| 5D | 2 | 5 |
| 6D | 0 | 9 |
| 7D or more | 2 | 19 |
| Total >=3 D | 10 | 101 |
Key Financials for Qiagen (QGEN)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $2.0 Bil | $2.0 Bil |
| Operating Income | $445.2 Mil | $199.9 Mil |
| Net Income | $341.3 Mil | $83.6 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ2 | 2025 FQ3 |
|---|---|---|
| Revenues | $533.5 Mil | $532.6 Mil |
| Operating Income | $136.0 Mil | $137.3 Mil |
| Net Income | $96.2 Mil | $130.0 Mil |
The losing streak QGEN stock is currently on doesn’t inspire much confidence among investors. In contrast, Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.